Towards precision medicine in psychosis: Benefits and challenges of multimodal 
multicenter studies—PSYSCAN: Translating neuroimaging findings from research 
into clinical practice

Tognin, S.; van Hell, H.; Merritt, K.; Rossum, I.; Bossong, M.; Kempton, M.; Modinos, G.; Fusar-Poli, P.; Mechelli, A.; Dazzan, P.; Maat, A.; de Haan, L.; Crespo-Facorro, B.; Glenthøj, B.; Lawrie, S.; McDonald, C.; Gruber, O.; van Amelsvoort, T.; Arango, C.; Kircher, T.; Nelson, B.; Galderisi, S.; Bressan, R.; Kwon, J.; Weiser, M.; Mizrahi, R.; Sachs, G.; Maatz, A.; Kahn, R.; McGuire, P.; PSYSCAN Consortium; Berger, Philipp

doi:10.1093/schbul/sbz067

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Towards precision medicine in psychosis: Benefits and challenges of multimodal multicenter studies—PSYSCAN: Translating neuroimaging findings from research into clinical practice

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

Tohnin_2021.pdf
(出版社版), 728KB

付随資料 (公開)

Tohnin_2021_Suppl.docx
(付録資料), 28KB

引用

Tognin, S., van Hell, H., Merritt, K., Rossum, I., Bossong, M., Kempton, M., Modinos, G., Fusar-Poli, P., Mechelli, A., Dazzan, P., Maat, A., de Haan, L., Crespo-Facorro, B., Glenthøj, B., Lawrie, S., McDonald, C., Gruber, O., van Amelsvoort, T., Arango, C., Kircher, T., Nelson, B., Galderisi, S., Bressan, R., Kwon, J., Weiser, M., Mizrahi, R., Sachs, G., Maatz, A., Kahn, R., McGuire, P., PSYSCAN Consortium, & Berger, P. (2020). Towards precision medicine in psychosis: Benefits and challenges of multimodal multicenter studies—PSYSCAN: Translating neuroimaging findings from research into clinical practice. Schizophrenia Bulletin, 46(2), 432-441. doi:10.1093/schbul/sbz067.

引用: https://hdl.handle.net/21.11116/0000-0009-2354-1

要旨

In the last 2 decades, several neuroimaging studies investigated brain abnormalities associated with the early stages of psychosis in the hope that these could aid the prediction of onset and clinical outcome. Despite advancements in the field, neuroimaging has yet to deliver. This is in part explained by the use of univariate analytical techniques, small samples and lack of statistical power, lack of external validation of potential biomarkers, and lack of integration of nonimaging measures (eg, genetic, clinical, cognitive data). PSYSCAN is an international, longitudinal, multicenter study on the early stages of psychosis which uses machine learning techniques to analyze imaging, clinical, cognitive, and biological data with the aim of facilitating the prediction of psychosis onset and outcome. In this article, we provide an overview of the PSYSCAN protocol and we discuss benefits and methodological challenges of large multicenter studies that employ neuroimaging measures.